BRAF and colorectal carcinoma: The primary analysis of BEACON CRC showed that Enco+Cetux, with or without Bini, significantly improved OS compared with control (Cetux+irinotecan, or Cetux+folinic acid, fluorouracil and irinotecan (FOLFIRI)) in patients with BRAF-V600-mutant mCRC.